CC 1088

Drug Profile

CC 1088

Alternative Names: CC 801; CDC 801

Latest Information Update: 16 Aug 2004

Price : $50

At a glance

  • Originator Celgene Corporation
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Crohn's disease; Myelodysplastic syndromes

Most Recent Events

  • 16 Aug 2004 Discontinued - Phase-II for Myelodysplastic syndromes in USA (unspecified route)
  • 21 Feb 2003 Discontinued - Phase-II for Crohn's disease in USA (unspecified route)
  • 21 Feb 2003 Discontinued - Phase-I for Crohn's disease in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top